Skip to main content
MedPathMedPath Home
Clinical Trials/KCT0004295
KCT0004295
Not yet recruiting
未知

Evaluation of diagnostic accuracy of PEPTEST, a non-invasive test for the diagnosis of gastroesophageal reflux disease

Samsung Medical Center0 sites100 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Samsung Medical Center
Enrollment
100
Status
Not yet recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Observational Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patient who have gastroesophageal reflux symptoms

Exclusion Criteria

  • •1\. Patients under 18 years old
  • •2\. Patients who have had past gastric or esophageal surgery
  • •3\. Patients taking proton pump inhibitors and histamine receptor blockers
  • •4\. Esophageal disorders such as achalasia and diffuse esophageal spasms
  • •5\. Patients with difficulty collecting saliva

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A clinical study in men with prostate cancer undergoing surgery to assess the accuracy of 99mTc-MIP-1404 imaging as compared to pathology resultsProstate Cancer within prostate gland and metastatic prostate cancer in regional lymph nodesMedDRA version: 14.1Level: LLTClassification code 10007113Term: Cancer of prostateSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-001864-30-BEMolecular Insight Pharmaceuticals, Inc100
Active, not recruiting
Not Applicable
Phase 2 study to assess the effectiviness of the investigational drug 99mTc-MIP-1404 in detecting prostate cancer tissue within the prostate gland and elsewhere in human body.Prostate Cancer within prostate gland and metastatic prostate cancer in regional lymph nodesMedDRA version: 15.0Level: LLTClassification code 10007113Term: Cancer of prostateSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-001864-30-HUMolecular Insight Pharmaceuticals, Inc100
Active, not recruiting
Phase 1
Phase 2 study to assess the effectiviness of the investigational drug 99mTc-MIP-1404 in detecting prostate cancer tissue within the prostate gland and elsewhere in human body.Prostate Cancer within prostate gland and metastatic prostate cancer in regional lymph nodesMedDRA version: 14.1Level: LLTClassification code 10007113Term: Cancer of prostateSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-001864-30-CZMolecular Insight Pharmaceuticals, Inc100
Active, not recruiting
Not Applicable
A clinical study in men with prostate cancer undergoing surgery to assess the accuracy of 99mTc-MIP-1404 imaging as compared to pathology resultsProstate Cancer within prostate gland and metastatic prostate cancer in regional lymph nodesMedDRA version: 14.1Level: LLTClassification code 10007113Term: Cancer of prostateSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2012-001864-30-NLMolecular Insight Pharmaceuticals, Inc100
Recruiting
Not Applicable
Pilot study of 68Ga-Pentixafor positron emission tomography (PET) imaging in multiple myeloma
ACTRN12617000593336Royal Brisbane and Women's Hospital10